A Lancet correspondence on EMPHASIS identifies patient selection limits, generalisability gaps, and statistical design issues that every stroke trial...
Alkeus starts Phase 3 NORTHSTAR trial of gildeuretinol for Stargardt disease, enrolling 230 patients across 55 sites in 11...
Ambros launches CRPS-RISE Phase 3 trial of neridronate for complex regional pain syndrome, enrolling 270 patients with warm-phase CRPS-1.
Potravitug shows improved viral clearance in BKPyV kidney transplant trial, with 64% achieving one-log reduction by week 20 versus...
Novo Nordisk's Bloomington facility hit with another FDA 483 — here's how manufacturing findings cascade into site enrollment holds,...
Ecnoglutide shows greater weight loss than semaglutide in interim trial data, with 12.8% versus 9.5% mean body weight reduction...
The SYNCHRONIZE-MASLD Phase 3 trial in Nature Medicine shows survodutide cutting liver fat by 64.3% vs placebo — here's...
Survodutide Phase III trial achieves 34% visceral fat and 63% liver fat reduction, positioning the dual agonist as a...
CagriSema beats semaglutide on weight loss and HbA1c reduction in type 2 diabetes trials, delivering 4-percentage-point greater weight loss...
Roche commits $2.3B to co-develop BTK degrader bexobrutideg with Nurix, targeting CLL patients resistant to conventional BTK inhibitors.
